VOR Vor Biopharma Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

   • Initial clinical data for Vor Bio's engineered HSC candidate VOR33 expected in 2H 2022
     
   • Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platform
   • In-house manufacturing facility in Cambridge, MA operational in 2022

   CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update. 

   "We remain fully focused on generating first-in-human clinical data from VBP101, our Phase 1/2a clinical trial of VOR33 in patients with relapsed/refractory AML, which will provide important proof of concept for our proprietary platform and has…

   View Full Article
2. 05 May 2022 Vor to Participate in Two Upcoming Investor Conferences

   CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcoming investor conferences:
   

   BofA Securities 2022 Healthcare Conference
   Date: Friday, May 13, 2022
   Virtual 1x1 meetings only

   H.C. Wainwright Global Investment Conference
   Presentation date: Tuesday, May 24, 2022
   Pre-recorded on-demand presentation available beginning at 7:00 AM ET

   The on-demand webcast of the presentation at the H.C. Wainwright Global Investment Conference be available on the Company's website at www.vorbio.com. An archived replay of the webcast will also be available.

   About Vor Bio
   Vor Bio is a…

   View Full Article
3. 25 April 2022 Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

   CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held April 27 to May 1 in Keystone, Colorado.
   

   The presentations include two posters and a workshop discussion featuring data on multiplex gene editing in human hematopoietic stem cells using various genome editing technologies. The data demonstrate how Vor Bio's novel platform, which genetically modifies healthy donor hematopoietic stem cells (HSCs) to remove select cell surface targets, enables targeted therapies to selectively destroy cancer cells while sparing the healthy…

   View Full Article
4. 14 April 2022 Vor Bio Announces Retirement of Chief Medical Officer

   CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to actively recruit patients into VBP101, the Company's Phase 1/2a first-in-human study of VOR33 in patients with AML who are at high risk of relapse. An executive search to replace Dr. Slapak is underway.
   

   "Our plan has always been for Dr. Slapak to build a team and infrastructure to successfully initiate the VBP101 clinical trial," said Dr. Robert Ang, President & Chief Executive Officer, Vor Bio. "Now that we are actively recruiting with data expected in the…

   View Full Article
5. 22 March 2022 Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

   Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop and manufacture cGMP nucleases.

   This collaboration strengthens Akron's portfolio of off-the-shelf gene editing technologies while broadening Vor Bio's collection of nucleases to engineer gene modified cell therapies. Vor Bio continues to strategically invest in its proprietary manufacturing capabilities for its engineered HSC and CAR-T programs. The companies will collaborate in the development and manufacture of starting materials needed to advance potentially transformative treatments for blood cancers into the clinic.

   "We…

   View Full Article